[Federal Register Volume 64, Number 1 (Monday, January 4, 1999)]
[Notices]
[Page 181]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 98-34814]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances Notice of Registration

    By Notice dated September 2, 1998, and published in the Federal 
Register on September 10, 1998, (63 FR 48523), Guilford 
Pharmaceuticals, Inc., Attn: Ross S. Laderman, 6611 Tributary Street, 
Baltimore, Maryland 21224, made application by renewal to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of cocaine a basic class of controlled substance listed in 
Schedule II.
    The firm plans to manufacture methyl-3-beta-(4-
trimethylstannylphenyl)-tropane-2-carboxylate as a final intermediate 
for the production of dopascan injection.
    No comments or objections have been received. DEA has considered 
the factors in Title 21, United States Code, Section 823(a) and 
determined that the registration of Guilford Pharmaceuticals to 
manufacture the listed controlled substances is consistent with the 
public interest at this time. DEA has investigated the firm on a 
regular basis to ensure that the company's continued registration is 
consistent with the public interest. These investigations have included 
inspection and testing of the company's physical security systems, 
audits of the company's records, verification of the company's 
compliance with state and local laws, and a review of the company's 
background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 
0.100 and 0.104, the Deputy Assistant Administrator, Office of 
Diversion Control, hereby orders that the application submitted by the 
above firm for registration as a bulk manufacturer of the basic class 
of controlled substance listed above is granted.

    Dated: December 23, 1998.
John H. King,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 98-34814 Filed 12-31-98; 8:45 am]
BILLING CODE 4410-09-M